Navigation Links
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Date:8/27/2010

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

"We welcome the FDA's decision to approve Tekamlo, as the treatment of high blood pressure remains a challenge for many patients, requiring multiple medications to control their condition," said David Epstein, Division Head of Novartis Pharmaceuticals. "This approval reinforces Novartis' commitment to cardiovascular research and to developing innovative and effective treatments for patients who have not reached their blood pressure goal."

The FDA approval of Tekamlo was based on clinical trial data involving more than 5,000 patients with mild-to-moderate high blood pressure. An eight-week, randomized, double-blind, placebo-controlled, multi-factorial study showed that the combination of Tekturna and amlodipine resulted in decreases in systolic/diastolic blood pressure at trough of 14-17/9-11 mmHg, compared to 4-9/3-4 mmHg for Tekturna alone, and 9-14/6-8 mmHg for amlodipine alone.

In two additional double-blind, active-controlled studies of similar design evaluating patients with moderate-to-severe high blood pressure (SBP 160 - 200 mmHg), Tekamlo demonstrated significantly greater reductions in systolic and diastolic blood pressures when compared to amlodipine alone. In one study of 443 Black patients, the systolic/diastolic treatment difference between Tekamlo and amlodipine was 5.2/3.8 mmHg at the primary endpoint of eight week
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Sevocity, a division of Conceptual MindWorks, Inc. (CMI), today ... as a preferred electronic health record (EHR) vendor with ... leading true Internet or cloud-based EHR. This enables Sevocity ... health record system with low start-up cost and affordable ...
... STAMFORD, Conn., July 20, 2011 A new online ... healthcare professionals, law enforcement, and community organizations combat the ... Purdue Pharma L.P . has developed RxSafetyMatters.org ... company and organizations with which it is partnering to ...
Cached Medicine Technology:Sevocity® Named Preferred EHR Vendor by CITIA-SC, South Carolina's Health IT Regional Extension Center (REC) 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 3
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... parallel with modern man ( Homo sapiens ), there were ... side by side, such as Neanderthals and the recently discovered ... survived. What was it in our genetic makeup that gave ... known about our unique genetic makeup as distinguished from our ... we are the only species among them ,to survive. Even ...
(Date:4/22/2014)... DC -- When mothers are exposed to trauma, illness, ... a single molecular trigger in brain cells that can ... stress disorder and some forms of autism. , Until ... have impacted the cells of a developing brain. Past ... herself to alcohol or drug abuse or she experiences ...
(Date:4/22/2014)... may be influenced by low exposure to testosterone in ... revealed how men,s testosterone levels may be determined before ... less of the hormone than others is important because ... of the hormone have been linked to obesity, diabetes ... cells responsible for producing testosterone in adults known ...
Breaking Medicine News(10 mins):Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Life stressors trigger neurological disorders, researchers find 2
... designed to treat chronic inflammatory conditions and leukemia resulted ... men involved in the trail becoming seriously ill. ... drug reaction. ,Dr. Ganesh Suntharalingam and colleagues ... immune system overreaction, known as a cytokine storm, was ...
... Clinton and Microsoft boss Bill Gates said inadequate access to ... combating the AIDS epidemic, in addresses to the largest ever ... continue to fight the stigma and stop people from being ... ,Both Clinton and Gates have donated billions of dollars ...
... be programmed to encourage fidgeting and other restless behaviors that ... research published by The American Physiological Society. ,The ... lean are more sensitive to a chemical produced in the ... such as fidgeting and other unconscious movements. Compared to rats ...
... good alternative for identifying risks for kidney disease, cardiovascular disease, ... a researcher at the San Francisco VA Medical Center, has ... incapable of picking up chronic health risks among the elderly., ... at risk for kidney disease, this is an important message: ...
... Neurosciences Institute in Rockville have claimed that the discovery ... patients// with Alzheimer's disease, could be developed as a ... ,The researchers explained that not only would be quick ... test for diagnosing Alzheimer's disease, which as of now ...
... Eighth International Conference on Mercury as a Global Pollutant, ... noted that Mercury pollution// can threaten the health of ... remote corners of the planet, but reducing mercury use ... declaration essentially says that mercury pollution is a problem ...
Cached Medicine News:Health News:Experimental Drug Causes Cytokine Storm 2Health News:Biological Basis Behind a Couch Potato 2Health News:Biological Basis Behind a Couch Potato 3Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 2Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 3Health News:Scientists Claim Developing A New Skin Test For The Early Detection Of Alzheimer’ 2Health News:Dangers Of Mercury 2
... System is designed to help physicians provide ... leg. Endovenous laser therapy is a patient-friendly ... of varicose veins., In endovenous laser therapy, ... the varicosed vein, generally through a small ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... #1 physician choice in laser treatment, brings ... superficial vein reflux. EVLT is a minimally ... stripping that effectively and safely treats varicose ... occlude the vein. The procedure is easy ...
Medicine Products: